Fifth Third Bancorp Has $3.52 Million Holdings in Medpace Holdings, Inc. $MEDP

Fifth Third Bancorp increased its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 1,820.9% during the 1st quarter, HoldingsChannel.com reports. The firm owned 7,338 shares of the company’s stock after purchasing an additional 6,956 shares during the period. Fifth Third Bancorp’s holdings in Medpace were worth $3,524,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. AQR Capital Management LLC raised its position in Medpace by 31.6% during the 4th quarter. AQR Capital Management LLC now owns 1,349,703 shares of the company’s stock worth $758,061,000 after purchasing an additional 324,293 shares during the last quarter. Wasatch Advisors LP grew its position in shares of Medpace by 14.0% in the 2nd quarter. Wasatch Advisors LP now owns 945,814 shares of the company’s stock valued at $296,853,000 after buying an additional 116,354 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Medpace by 3.8% in the fourth quarter. Geode Capital Management LLC now owns 667,298 shares of the company’s stock valued at $374,836,000 after buying an additional 24,625 shares during the period. Invesco Ltd. increased its stake in shares of Medpace by 18.9% in the third quarter. Invesco Ltd. now owns 537,407 shares of the company’s stock valued at $276,313,000 after buying an additional 85,517 shares during the period. Finally, Arrowstreet Capital Limited Partnership raised its position in shares of Medpace by 19.4% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 375,033 shares of the company’s stock worth $210,637,000 after acquiring an additional 60,883 shares during the last quarter. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the company. Wall Street Zen lowered Medpace from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Mizuho increased their target price on shares of Medpace from $495.00 to $586.00 and gave the company an “outperform” rating in a research report on Monday, July 13th. Royal Bank Of Canada lowered their price target on shares of Medpace from $522.00 to $484.00 and set an “outperform” rating for the company in a report on Friday, April 24th. Robert W. Baird reaffirmed a “neutral” rating and issued a $547.00 price objective (up from $477.00) on shares of Medpace in a research note on Wednesday, July 8th. Finally, Jefferies Financial Group lowered shares of Medpace from a “buy” rating to a “hold” rating and upped their price objective for the company from $490.00 to $515.00 in a research note on Tuesday, July 7th. Two investment analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $469.50.

Insider Buying and Selling

In related news, General Counsel Stephen P. Ewald sold 16,349 shares of the company’s stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the transaction, the general counsel directly owned 20,343 shares of the company’s stock, valued at approximately $9,154,350. This represents a 44.56% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 20.50% of the stock is owned by insiders.

Medpace Price Performance

Shares of NASDAQ MEDP opened at $537.73 on Monday. The firm has a market cap of $15.36 billion, a PE ratio of 33.80, a P/E/G ratio of 2.69 and a beta of 1.15. Medpace Holdings, Inc. has a 12-month low of $306.70 and a 12-month high of $628.92. The company’s fifty day simple moving average is $478.10 and its 200 day simple moving average is $494.23.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings results on Wednesday, April 22nd. The company reported $4.28 EPS for the quarter, topping analysts’ consensus estimates of $3.74 by $0.54. Medpace had a net margin of 17.19% and a return on equity of 120.89%. The business had revenue of $706.60 million during the quarter, compared to analysts’ expectations of $697.82 million. During the same period last year, the company posted $3.67 earnings per share. The business’s quarterly revenue was up 26.5% on a year-over-year basis. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, equities analysts predict that Medpace Holdings, Inc. will post 17.04 earnings per share for the current year.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.